Media stories about Stryker (NYSE:SYK) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Stryker earned a news impact score of 0.20 on Accern’s scale. Accern also assigned news coverage about the medical technology company an impact score of 46.6645721382859 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Daxor Corporation (DXR) Ex-Dividend Date Scheduled for January 05, (nasdaq.com)
- Global Surgical Table Market Report 2017: Trends, Forecast and Competitive Analysis Featuring Maquet, Steris, Trumpf, Stryker, and Mizuho (markets.financialcontent.com)
- Stryker Corporation (SYK) RSI at 63.24 signal for breakout? – Times Money (thetimesmoney.org)
- Stryker’s Global Foothold Strong Amid Product Recall Issue – Nasdaq (nasdaq.com)
- Stryker Corporation (NYSE:SYK) – Glowing Stock’s Review – Nasdaq Journal (press release) (nasdaqjournal.com)
Several analysts have issued reports on the stock. Wells Fargo & Co restated an “outperform” rating and set a $174.00 price target (up from $166.00) on shares of Stryker in a research report on Tuesday. They noted that the move was a valuation call. JPMorgan Chase & Co. upgraded shares of Stryker from a “neutral” rating to an “overweight” rating in a research report on Tuesday. BMO Capital Markets upgraded shares of Stryker to a “market perform” rating and set a $163.00 price target for the company in a research report on Tuesday, December 12th. Needham & Company LLC restated a “hold” rating on shares of Stryker in a research report on Thursday, December 7th. Finally, ValuEngine lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have given a buy rating to the company. Stryker has an average rating of “Hold” and an average price target of $154.60.
Stryker (SYK) traded down $0.05 during trading on Thursday, hitting $158.74. 862,436 shares of the stock were exchanged, compared to its average volume of 1,107,279. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $59,410.00, a price-to-earnings ratio of 33.85, a P/E/G ratio of 2.26 and a beta of 0.78. Stryker has a one year low of $116.50 and a one year high of $160.62.
Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. Stryker had a net margin of 14.67% and a return on equity of 24.11%. The business had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.97 billion. During the same period last year, the business posted $1.39 earnings per share. Stryker’s quarterly revenue was up 6.1% compared to the same quarter last year. sell-side analysts anticipate that Stryker will post 6.47 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This is a positive change from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 1.18%. Stryker’s dividend payout ratio (DPR) is 40.09%.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares in the company, valued at $12,925,375.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.40% of the company’s stock.
WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Stryker (SYK) Share Price” was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2018/01/04/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-stryker-syk-share-price.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.